T-Cell Lymphoma Treatment Strategies

T-cell lymphomas encompass a heterogeneous group of aggressive haematological malignancies arising from mature T cells or natural killer cells and include entities such as peripheral T-cell lymphoma (PTCL), extranodal NK/T-cell lymphoma (ENKTL) and enteropathy-associated T-cell lymphoma (EATL). Standard chemotherapy regimens based on anthracyclines have yielded limited success, with high rates of relapse and treatment resistance. Recent advances in genomic profiling have revealed recurrent mutations in signalling pathways, epigenetic regulators and immune checkpoints, thereby informing targeted therapeutic strategies. Among these, agents directed against the PD-1/PD-L1 axis, histone deacetylase inhibitors, antibody–drug conjugates and small-molecule inhibitors of the JAK-STAT pathway have shown promise. Moreover, cellular therapies such as chimeric antigen receptor T cells and EBV-specific cytotoxic T lymphocytes are under active investigation. Combination approaches integrating standard chemotherapy with novel immunomodulatory or epigenetic agents aim to overcome resistance mechanisms and improve long-term outcomes. These developments mark a shift towards precision medicine in T-cell lymphoma, aligned with molecular classification and risk-adapted treatment.

Research from Nature Portfolio

Analyses of activating mutations in STAT3 and STAT5B in NK/T-cell and γδ-T-cell lymphomas have underscored the central role of the JAK-STAT pathway in tumour survival and proliferation, demonstrating that selective JAK1/2 inhibitors can suppress mutant-driven signalling and restrict malignant cell growth. This work provides a mechanistic rationale for incorporating JAK inhibitors into therapeutic regimens for subtypes harbouring such mutations. Additionally, comprehensive exome sequencing of Type II enteropathy-associated T-cell lymphoma has identified inactivating lesions in the histone methyltransferase SETD2 in the vast majority of cases, accompanied by recurrent mutations in STAT5B, JAK3 and TP53. These findings delineate a distinct molecular signature for EATL-II and suggest that restoration of epigenetic control, combined with targeted blockade of aberrant kinases, could form the basis of future treatment strategies for this rare intestinal lymphoma.

T-Cell Lymphoma Treatment Strategies publication trend

The graph below shows the total number of articles in t-cell lymphoma treatment strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Extranodal NK/T-cell lymphoma: An aggressive lymphoma of NK or cytotoxic T-cell origin, often EBV-associated and involving extranodal sites.

Histone deacetylase inhibitor (HDACi): A compound that alters chromatin structure and gene expression by preventing removal of acetyl groups from histone proteins.

Programmed cell death protein 1 (PD-1): An immune-checkpoint receptor on T cells that, when engaged by PD-L1, dampens anti-tumour immunity.

Chimeric antigen receptor T cell (CAR-T): Genetically engineered T lymphocytes expressing synthetic receptors targeting tumour-associated antigens.

JAK-STAT pathway: A cytokine-activated signalling cascade that regulates gene expression and cell survival; frequently mutated in T-cell lymphomas.

Objective response rate (ORR): The proportion of patients whose tumour burden is reduced by a predefined amount.

Progression-free survival (PFS): The duration during which a patient’s disease does not worsen under treatment.

Duration of response (DOR): The time span from initial tumour response until disease progression.

References

1. Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II study. Signal Transduction and Targeted Therapy (2024).
2. Therapeutic challenges in peripheral T-cell lymphoma. Molecular Cancer (2024).
3. Novel target and treatment agents for natural killer/T-cell lymphoma. Journal of Hematology & Oncology (2023).
4. Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells. Nature Communications (2015).
5. Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations. Nature Communications (2016).